Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NovoSeven as a universal haemostatic agent.

U Hedner1

  • 1Novo Nordisk A/S, Health Care Discovery, Gentofte, Denmark. uhe@novo.dk

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|June 13, 2000
PubMed
Summary

Recombinant activated factor VII (rFVIIa) effectively induces hemostasis, even without FVIII/FIX, by activating platelets. This treatment shows promise for hemophilia, platelet disorders, and liver disease patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive improvement in wound healing with increased therapy in haemophilia B mice.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Activated factor VII: my story.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Joint protection in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2011

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Hemostasis initiation involves tissue factor (TF) and activated factor VII (FVIIa) complex formation.
  • TF is exposed to blood upon tissue damage, and FVIIa requires TF for enzymatic activity.
  • Recombinant activated factor VII (rFVIIa) can induce hemostasis independently of FVIII and FIX.

Purpose of the Study:

  • To evaluate the hemostatic efficacy of rFVIIa in various clinical scenarios.
  • To investigate the TF-independent mechanism of rFVIIa action on platelets.
  • To assess rFVIIa's utility in hemophilia, FVII deficiency, platelet disorders, liver disease, and warfarin reversal.

Main Methods:

  • Administration of high-dose rFVIIa (approx. 100 microg/kg).
  • In vitro studies on platelet binding and thrombin generation.

Related Experiment Videos

  • Clinical case studies and treatment of bleeding episodes.

    • Main Results:

    • rFVIIa successfully induced hemostasis in FVIII/FIX deficient hemophilia patients.
    • rFVIIa effectively managed bleeding in patients with congenital FVII deficiency.
    • rFVIIa demonstrated efficacy in patients with Glanzmann's and Bernard-Soulier's thrombasthenia.
    • rFVIIa normalized prothrombin time in liver disease and warfarin-treated patients.

    Conclusions:

    • rFVIIa is a potent procoagulant agent capable of inducing hemostasis through TF-dependent and TF-independent pathways.
    • rFVIIa offers a valuable therapeutic option for managing bleeding in diverse hemostatic and coagulation disorders.
    • The TF-independent platelet activation by rFVIIa broadens its clinical applicability.